Remepy: Valuation, Funding & Investors
Remepy develops hybrid drugs—therapeutic assets that combine conventional pharmaceutical agents with proprietary non‑pharmaceutical treatment protocols. The company applies AI-driven measurement and adaptation to deliver and optimize those protocols, operating at the intersection of drug development, digital therapeutics, and treatment personalization.
Leadership & Board
Key Executives
- Founder
- Michal Tsur and Or Shoval
- CSO
- Amir Amedi
- CTO
- Eran Etam
- Current Number of Employees
- 90
- Current LinkedIn Followers
- 8,086
Latest Estimated Valuation
- Total Amount Raised
- $46M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $36M
- Latest Funding Round
- Series A
Employee Trend
Remepy had 90 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
90Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Remepy had 8,086 followers as of November 9, 2026. The number of followers increased by 92 (1.15%) week-over-week.
8,086Latest Followers Count
92(1.15%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 12, 2026 | Series A | $36.00M | ― |
| Jun 01, 2024 | Seed Round | $10.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| M Ventures | Series A |
| NFX | Series A |
| Vine Ventures | Series A |
| Qumra Capital | Series A |
| TechAviv | Series A |
| 97212 Ventures | Series A |
| Fresh Fund | Series A |
| PsyMed Ventures | Series A |
Similar Companies
A snapshot of private companies similar to Remepy, helping you discover and navigate related company profiles.







